                         SEQUENCE LISTING

<110>  Lion TCR Pte Ltd
 
<120>  An HBV Antigen Specific Binding Molecules and Fragments Thereof

<130>  2016.P00486

<160>  39    

<170>  PatentIn version 3.5

<210>  1
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR 1a


<220>
<221>  VARIANT
<222>  (2)..(2)
<223>  Xaa is either Ser or Ile

<400>  1

Asp Xaa Ser Ser Thr Tyr 
1               5       


<210>  2
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2a

<400>  2

Ile Phe Ser Asn Met Asp Met 
1               5           


<210>  3
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3a

<400>  3

Ala Glu Thr Leu Asp Asn Tyr Gly Gln Asn Phe Val 
1               5                   10          


<210>  4
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1b

<400>  4

Asp Phe Gln Ala Thr Thr 
1               5       


<210>  5
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2b

<400>  5

Ser Asn Glu Gly Ser Lys Ala 
1               5           


<210>  6
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3b

<400>  6

Ser Ala Val Asp Arg Asp Glu Pro Phe His Ser Asn Gln Pro Gln His 
1               5                   10                  15      


<210>  7
<211>  18
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  CDR1a

<400>  7
gacagctcct ccacctac                                                     18


<210>  8
<211>  21
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  CDR2a

<400>  8
attttttcaa atatggacat g                                                 21


<210>  9
<211>  36
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  CDR3a

<400>  9
gcagagacct tggataacta tggtcagaat tttgtc                                 36


<210>  10
<211>  18
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  CDR1b

<400>  10
gactttcagg ccacaact                                                     18


<210>  11
<211>  21
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  CDR2b

<400>  11
tccaatgagg gctccaaggc c                                                 21


<210>  12
<211>  48
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  CDR3b

<400>  12
agtgctgtag acagggatga acctttccat agcaatcagc cccagcat                    48


<210>  13
<211>  18
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  CDR1a

<400>  13
gactcctcta gtacctac                                                     18


<210>  14
<211>  21
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  CDR2a

<400>  14
atcttttcca acatggacat g                                                 21


<210>  15
<211>  36
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  CDR3a

<400>  15
gccgagaccc tggacaacta cggccagaat ttcgtg                                 36


<210>  16
<211>  18
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  CDR1b

<400>  16
gacttccagg ccaccaca                                                     18


<210>  17
<211>  21
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  CDR2b

<400>  17
agcaacgaag gatccaaagc c                                                 21


<210>  18
<211>  48
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  CDR3b

<400>  18
tcagcagtgg accgagatga acctttccac agcaaccagc cacagcat                    48


<210>  19
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  HBV Gen C

<400>  19

Phe Leu Gly Pro Leu Leu Val Leu Gln Ala 
1               5                   10  


<210>  20
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  HBV Gen B

<400>  20

Leu Leu Gly Pro Leu Leu Val Leu Gln Ala 
1               5                   10  


<210>  21
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  HBV Gen C

<400>  21

Ser Thr Thr Ser Gly Phe Leu Gly Pro Leu Leu Val Leu Gln Ala 
1               5                   10                  15  


<210>  22
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  HBV Gen B

<400>  22

Ser Thr Thr Ser Gly Leu Leu Gly Pro Leu Leu Val Leu Gln Ala 
1               5                   10                  15  


<210>  23
<211>  14
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  HBV Gen B and C

<400>  23

Val Leu Gln Ala Gly Phe Phe Leu Leu Thr Arg Ile Leu Thr 
1               5                   10                  


<210>  24
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1a

<400>  24

Asp Ser Ser Ser Thr Tyr 
1               5       


<210>  25
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1a

<400>  25

Asp Ile Ser Ser Thr Tyr 
1               5       


<210>  26
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  HBVC/D Env 34-10

<400>  26

Phe Leu Gly Pro Leu Leu Val Leu Gln Ala Gly 
1               5                   10      


<210>  27
<211>  14
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  HBV Gen C

<400>  27

Ser Thr Thr Ser Gly Phe Leu Gly Pro Leu Leu Val Leu Gln 
1               5                   10                  


<210>  28
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  HBV Gen C

<400>  28

Phe Leu Gly Pro Leu Leu Val Leu Gln Ala Gly Phe Phe Leu Leu 
1               5                   10                  15  


<210>  29
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  HBV Gen B

<400>  29

Leu Leu Gly Pro Leu Leu Val Leu Gln Ala Gly Phe Phe Leu Leu 
1               5                   10                  15  


<210>  30
<211>  25
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  HBV Gen C

<400>  30

Ser Thr Thr Ser Gly Phe Leu Gly Pro Leu Leu Val Leu Gln Ala Gly 
1               5                   10                  15      


Phe Phe Leu Leu Thr Arg Ile Leu Thr 
            20                  25  


<210>  31
<211>  25
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  HBV Gen B

<400>  31

Ser Thr Thr Ser Gly Leu Leu Gly Pro Leu Leu Val Leu Gln Ala Gly 
1               5                   10                  15      


Phe Phe Leu Leu Thr Arg Ile Leu Thr 
            20                  25  


<210>  32
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  HBVB Env 34-1

<400>  32

Gly Leu Leu Gly Pro Leu Leu Val Leu Gln 
1               5                   10  


<210>  33
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  HBVB Env 34-2

<400>  33

Gly Leu Leu Gly Pro Leu Leu Val Leu Gln Ala 
1               5                   10      


<210>  34
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  HBVB 34-4

<400>  34

Leu Gly Pro Leu Leu Val Leu Gln Ala 
1               5                   


<210>  35
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  HBVB Env 34-5

<400>  35

Leu Leu Gly Pro Leu Leu Val Leu Gln Ala Gly 
1               5                   10      


<210>  36
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  HBVB Env 34-6

<400>  36

Leu Gly Pro Leu Leu Val Leu Gln Ala Gly 
1               5                   10  


<210>  37
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  HBVB Env 34-7

<400>  37

Gly Pro Leu Leu Val Leu Gln Ala Gly 
1               5                   


<210>  38
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  HBVC/D Env 34-8

<400>  38

Gly Phe Leu Gly Pro Leu Leu Val Leu Gln Ala 
1               5                   10      


<210>  39
<211>  170
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  pCR 4Blunt-TOPO

<400>  39
cacacaggaa acagctatga ccatgattac gccaagctca gaattaaccc tcactaaagg       60

gactagtcct gcaggtttaa acgaattcgc ccttaagggc gaattcgcgg ccgctaaatt      120

caattcgccc tatagtgagt cgtattacaa ttcactggcc gtcgttttac                 170


